Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples